Evolving Treatment Options and Care Management Strategies: A Multiple Sclerosis Update for Pharmacists Web Activity

Aimee M. Banks, PharmD, BCPS
Clinical Pharmacist
Vanderbilt University Medical Center
Multiple Sclerosis Clinic

Click here for biography

Scott Newsome, DO, MSCS
Assistant Professor of Neurology
Director, Neurology Outpatient Services
Director, Neurology Infusion Center
Johns Hopkins Neuroimmunology and
Neuroinfectious Diseases                   
Johns Hopkins Hospital

Click here for biography



Multiple sclerosis (MS) is a chronic immune-mediated degenerative disorder of the central nervous system (CNS). It is estimated that 400,000 individuals in the United States are affected, although this figure may not reflect current numbers as there has not been a robust national assessment of the prevalence of MS since 1975. Onset typically occurs between the ages of 20 and 40 years; consequently, MS is the leading cause of non-traumatic disability in young adults. Women are affected approximately twice as often as men. Yet, despite its relatively low prevalence, MS is characterized by a significant economic burden due to its extensive morbidity and requirement for chronic treatment.

Health-system pharmacists (HSPs) often serve as the intermediary between physicians and patients; a position that provides unique insights into treatment-specific needs of patients with MS. This activity is designed to educate HSPs on current and emerging MS treatment options, symptom management, multidisciplinary care planning, and patient counseling in order to improve patient care and outcomes in MS patients

At the conclusion of this activity, participants should be able to demonstrate improved ability to: 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-328-H01-P)

Type of Activity: Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Name of Faculty or Presenter Reported Financial Relationship
Aimee M. Banks, PharmD, BCPS Dr. Banks has nothing to disclose
Scott Newsome, DO, MSCS Consulting fees from Biogen, Genentech, Celgene, Gerson Lehrman Group; Research grants from Biogen, Novartis, Genentech; paid directly to Institution

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period of March 28, 2018, through September 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.


There is no fee for this educational activity.